The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.

Researchers have identified a promising new strategy to treat autoimmune diseases by targeting a specific molecular interaction within immune cells.

May marks Lupus Awareness Month, a time to raise understanding of a condition that affects millions. Lupus causes the immune system to attack healthy tissues, often impacting the skin, joints, and ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

Italian researchers reporting in the journal Cancers found a 32% increase in the odds for cancer in the first year after a ...

Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a single-use autoinjector for adult patients with active, ...

Scientists may have pinpointed a primary cause of lupus, a chronic autoimmune disease. Researchers from Northwestern Medicine in Chicago and Brigham and Women’s Hospital in Boston claim they have ...

Neuropsychiatric symptoms, including nightmares and hallucinatory "daymares," may be a more important aspect of systemic lupus erythematosus (SLE) than formerly recognized, according to a qualitative ...

The optimal management of asymptomatic serological reactivation in lupus nephritispatients has been unclear, so a trial tested preemptive treatment.

Lupus nephritis biomarkers show promise, but most lack strong evidence for clinical use. Read more on key findings.